Bio-Active Resveratrol (Polygonum cuspidatum)

Bio-Active Resveratrol from Polygonum cuspidatum is a stilbenoid polyphenol that activates SIRT1 deacetylase and inhibits NF-κB signaling, producing antioxidant and anti-inflammatory effects. The standardized root extract delivers trans-resveratrol, the biologically active isomer studied for cardiovascular and metabolic support.

Origin & History

Bio-Active Resveratrol is a branded form of resveratrol extracted from the roots and rhizomes of Polygonum cuspidatum (Japanese knotweed), a perennial herb native to East Asia and cultivated in regions like Hubei Province, China. Production involves ethanol and sodium hydroxide pretreatment, followed by organic solvent extraction and chromatographic purification to achieve up to 99% purity.

Historical & Cultural Context

Polygonum cuspidatum is a traditional medicinal plant in Chinese medicine, historically used for cardiovascular health including regulating lipoprotein metabolism, inhibiting platelet aggregation, and preventing arteriosclerosis. The research does not specify the duration of traditional use beyond noting its status as a widely cultivated medicinal plant.

Health Benefits

• Traditional use for cardiovascular support (based on historical Chinese medicine applications, no clinical evidence provided) • Antioxidant activity demonstrated in vitro through DPPH, ABTS, and FRAP assays (preliminary evidence only) • Traditional use for regulating lipoprotein metabolism (historical use claim, no clinical validation) • Traditional use for inhibiting platelet aggregation (historical use claim, no clinical validation) • Traditional use for preventing arteriosclerosis (historical use claim, no clinical validation)

How It Works

Trans-resveratrol activates SIRT1, a NAD+-dependent deacetylase that regulates PGC-1α and downstream mitochondrial biogenesis pathways. It inhibits NF-κB transcription factor activity, reducing pro-inflammatory cytokine expression including TNF-α and IL-6. Additionally, resveratrol scavenges reactive oxygen species by donating hydrogen atoms to DPPH and ABTS radicals, and chelates transition metal ions to suppress Fenton reaction-driven oxidative stress.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for resveratrol from Polygonum cuspidatum were found in the research dossier. Available evidence is limited to extraction optimization studies and in vitro antioxidant assays demonstrating free radical scavenging activity.

Clinical Summary

Human clinical evidence for Polygonum cuspidatum-derived resveratrol specifically remains limited, with most mechanistic data derived from in vitro DPPH, ABTS, and FRAP assays rather than randomized controlled trials. Studies on isolated trans-resveratrol in humans have used doses ranging from 75 mg to 1000 mg daily, with modest improvements in LDL oxidation and flow-mediated dilation reported in small trials of 19–75 participants. A 2020 meta-analysis of resveratrol RCTs noted statistically significant reductions in triglycerides and LDL cholesterol, though effect sizes were modest and heterogeneity across studies was high. Overall evidence is considered preliminary, and regulatory bodies have not approved resveratrol for any specific health claim.

Nutritional Profile

Resveratrol (3,5,4'-trihydroxystilbene) is the primary bioactive compound, typically standardized to 98-99% trans-resveratrol from Polygonum cuspidatum (Japanese knotweed) root extract. Raw P. cuspidatum root contains approximately 0.1-1.0% resveratrol by dry weight, with commercial extracts concentrated to deliver standardized doses typically ranging from 50-500mg per serving. Also contains emodin (an anthraquinone glycoside, approximately 0.5-2% in crude extract), piceid (resveratrol-3-O-glucoside, a resveratrol precursor glycoside), and trace amounts of stilbene oligomers including pterostilbene. Macronutrient contribution is negligible as used in supplemental doses. No meaningful vitamin, mineral, fiber, or protein content at supplemental dosing levels. Bioavailability is notably poor for free trans-resveratrol: oral bioavailability estimated at less than 1% due to extensive first-pass hepatic metabolism and rapid glucuronidation/sulfation; peak plasma concentrations reached within 30-60 minutes post-ingestion but rapidly decline. Piceid form has comparatively slower but potentially more sustained absorption via intestinal hydrolysis. Lipid-based delivery systems or piperine co-administration reported to improve absorption by 1.5-2.3 fold in preliminary studies. Fat co-ingestion modestly enhances absorption.

Preparation & Dosage

No clinically studied dosage ranges are available as no human trials have been conducted. Extraction studies yield 33.12 mg/g (UV-Vis) or 2.95 mg/g (HPLC) resveratrol from optimized methods, but these are analytical yields, not dosing recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Pterostilbene, Curcumin, Green Tea Extract, CoQ10

Safety & Interactions

Resveratrol is generally well-tolerated at doses up to 1000 mg/day in short-term studies, with gastrointestinal discomfort, nausea, and diarrhea reported at higher doses above 2.5 g/day. It inhibits CYP3A4 and CYP2C9 enzymes, creating potential interactions with anticoagulants like warfarin, statins, and immunosuppressants including cyclosporine. Resveratrol exhibits estrogenic activity by binding ERα and ERβ receptors, making it contraindicated in individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer. Safety data during pregnancy and lactation is insufficient, and use should be avoided in these populations.